NOW SCHEDULING · SALT LAKE COUNTY, UTAH

Spravato® (Esketamine) Treatment for Treatment-Resistant Depression

If you have tried two or more antidepressants and depression is still getting in the way, Spravato® (esketamine) nasal spray may be an option. Mountain View Family Therapy offers Spravato treatment at our Draper office, a certified SPRAVATO® REMS treatment center, given under the supervision of a healthcare provider and coordinated with the rest of your care. Treatment visits begin September 25, 2026.

Important Safety Information is at the bottom of this page.

What Is Spravato?

Spravato® (esketamine) is a prescription nasal spray, approved by the FDA, for adults with treatment-resistant depression. It is taken in a healthcare setting under the supervision of a healthcare provider, never at home. Spravato is believed to work differently from oral antidepressants, acting on a pathway in the brain where a chemical called glutamate helps balance well-being and depression. The exact way Spravato works is not fully understood.

Mountain View Family Therapy is a mental health practice with offices in Riverton and Draper, Utah, providing counseling and psychiatric medication management for children, teens, adults, couples, and families, with telehealth across Utah. Spravato is offered to adults at our Draper office as part of that care.

What Spravato is approved for

SPRAVATO® is a prescription medicine used:

  • with or without an antidepressant taken by mouth, to treat adults with treatment-resistant depression (TRD)
  • with an antidepressant taken by mouth, to treat depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts or actions

SPRAVATO® is not for use as a medicine to prevent or relieve pain (anesthetic). It is not known if SPRAVATO® is safe or effective as an anesthetic medicine.

It is not known if SPRAVATO® is safe and effective for use in preventing suicide or in reducing suicidal thoughts or actions. SPRAVATO® is not for use in place of hospitalization if your healthcare provider determines that hospitalization is needed, even if improvement is experienced after the first dose of SPRAVATO®.

It is not known if SPRAVATO® is safe and effective in children.

Product photo from the Johnson & Johnson treatment center toolkit

Is Spravato Right for Me?

Spravato is for adults. It is prescribed when depression has not responded well enough to oral antidepressants.

If you’ve taken two or more oral antidepressants and still experience symptoms of depression, you might have treatment-resistant depression (TRD). Spravato is the only nasal spray treatment indicated for people who’ve taken two or more oral antidepressants and still experience symptoms of depression.

Spravato is not for everyone. Certain blood vessel conditions and a history of bleeding in the brain rule it out, it is not for use in children, and it should not be taken during pregnancy. Heart problems, high blood pressure, liver problems, and a history of psychosis need to be discussed with your healthcare provider before you start. Please read the Important Safety Information on this page and talk with your provider about your full medical history.

If you are in crisis or thinking about suicide, call or text 988 (the Suicide and Crisis Lifeline) now, or go to the nearest emergency room.

How to get started

  • Current clients: talk with your therapist or your medication provider. They can help you decide whether a Spravato evaluation makes sense.
  • New clients: contact our office and ask about Spravato. We will walk you through the next steps.

What Spravato Treatment Looks Like at Mountain View

Treatment happens in our Draper office, not at home

Spravato is only available through a restricted program called the SPRAVATO® REMS, and it can only be given at healthcare settings certified in that program. You take the nasal spray yourself, under the supervision of a healthcare provider, and the medicine never leaves the office.

Plan on at least two hours

After each dose, a healthcare provider monitors you for at least two hours and decides when you are ready to leave. Your blood pressure is checked before your dose and during the monitoring period. Bring something to read or listen to.

You will need a ride home

You cannot drive, operate machinery, or do anything that requires you to be completely alert until the next day, after a restful sleep. Arrange for a family member or friend to drive you home from every treatment visit.

Before each visit

Do not eat for at least two hours before your dose, and do not drink liquids for at least 30 minutes before. If you use a nasal corticosteroid or nasal decongestant, take it at least one hour before your treatment.

A typical treatment schedule

Spravato is given twice a week for the first four weeks. After that, you and your healthcare provider decide together whether to continue, at what dose, and how often. The schedule in the second month is typically once a week, and from the third month on it is once a week or every other week.

With or without an oral antidepressant

For treatment-resistant depression, Spravato can be used with or without an antidepressant taken by mouth. Your prescriber will decide what makes sense for you. Do not stop or change any medication on your own.

Coordinated with the rest of your care

Therapy and medication management happen under one roof at Mountain View Family Therapy, so the providers involved in your care can communicate directly about how you are doing.

Treatment room photo from the Johnson & Johnson toolkit

Your Spravato Care Team

Spravato treatment at Mountain View Family Therapy is overseen by Hannah Backman, DNP, PMHNP and Anne Willardson, PMHNP, psychiatric nurse practitioners at our Draper office. They evaluate whether Spravato is a fit, prescribe and supervise each treatment visit, and coordinate with your therapist and any other prescriber involved in your care.

Spravato and Ketamine Are Not the Same Thing

Spravato is derived from ketamine, but there are differences. Both Spravato and ketamine are Schedule III controlled substances under the US Controlled Substances Act. Spravato is an FDA-approved nasal spray for treatment-resistant depression; ketamine has not been approved by the FDA to treat depression. Spravato is the treatment we offer.

Cost and Insurance

Coverage for Spravato varies by plan and usually requires prior authorization, which our office handles for you. Before you start, contact our office and we will help you understand what your plan covers and what to expect for cost. Mountain View Family Therapy is in network with many major plans; the current list is on our rates and insurance page. Johnson & Johnson also offers cost support resources for eligible patients; details are at SPRAVATO.com.

Spravato Questions

Is Spravato covered by insurance?

It depends on your plan. Coverage varies and usually requires prior authorization, which our office handles for you. Contact our office and we will help you check your benefits before you start.

Where is Spravato offered?

At our Draper office, 584 E 12300 S, Suite 7, Draper, UT 84020, which is a certified SPRAVATO® REMS treatment center. Therapy and medication management are also available at our Riverton office, and telehealth is available across Utah.

When can I start?

Spravato treatment visits begin September 25, 2026. Contact our office now to ask about an evaluation so you are ready to begin.

How much does Spravato cost?

Your cost depends on your insurance coverage and any prior authorization. Call our office for current self-pay information, and see SPRAVATO.com for the manufacturer’s cost support resources.

How long does a Spravato visit take?

Plan on at least two hours after taking your dose. A healthcare provider must monitor you for at least two hours and will decide when you are ready to leave.

Can I drive myself home?

No. Do not drive, operate machinery, or do anything that requires you to be completely alert until the next day, after a restful sleep. Arrange a ride home for every treatment visit.

Is Spravato the same as ketamine?

No. Spravato is derived from ketamine, but there are differences. Spravato is an FDA-approved nasal spray for treatment-resistant depression; ketamine has not been approved by the FDA to treat depression. Both are Schedule III controlled substances.

Do I have to stop taking my antidepressant?

Not necessarily. For treatment-resistant depression, Spravato can be used with or without an oral antidepressant. Your prescriber will decide what is right for you. Never stop or change a medication on your own.

What are the most common side effects?

The most common side effects of Spravato include feeling disconnected from yourself, your thoughts, feelings and things around you; dizziness; nausea; feeling sleepy; spinning sensation; decreased feeling of sensitivity (numbness); feeling anxious; lack of energy; increased blood pressure; vomiting; feeling drunk; headache; and feeling very happy or excited. If these occur, they usually happen right after taking Spravato and go away the same day. Serious side effects are possible. See the Important Safety Information below.

How soon might I notice a change?

In the manufacturer’s short-term study, more patients taking Spravato plus an oral antidepressant showed a reduction in depressive symptoms at four weeks than those taking placebo plus an oral antidepressant, and most of that reduction was seen at 24 hours. Individual results vary. Your healthcare provider will evaluate how you are doing at the end of the first four weeks to decide whether treatment should continue.

Do I need to be a current client?

No. New clients are welcome to contact our office to ask about a Spravato evaluation. Current clients can start by talking with their therapist or medication provider.

Who should not take Spravato?

Spravato is not for use in children. Do not take it if you have blood vessel (aneurysmal vascular) disease, an abnormal connection between your veins and arteries (arteriovenous malformation), a history of bleeding in the brain, or an allergy to esketamine, ketamine, or any of the other ingredients in Spravato. You should not take Spravato if you are pregnant. Tell your healthcare provider about all of your medical conditions and every medicine you take before starting. The full list is in the Important Safety Information below.

Learn More About Spravato

These resources are published by Johnson & Johnson, the maker of Spravato.

Important Safety Information

What is the most important information I should know about SPRAVATO®?

SPRAVATO® can cause serious side effects, including:

  • Sedation, dissociation, and respiratory depression. SPRAVATO® may cause sleepiness (sedation), fainting, dizziness, spinning sensation, anxiety, or feeling disconnected from yourself, your thoughts, feelings, space and time (dissociation), breathing problems (respiratory depression and respiratory arrest).
    • Tell your healthcare provider right away if you feel like you cannot stay awake or if you feel like you are going to pass out.
    • Your healthcare provider must monitor you for serious side effects for at least 2 hours after taking SPRAVATO®. Your healthcare provider will decide when you are ready to leave the healthcare setting.
  • Abuse and misuse. There is a risk for abuse and misuse with SPRAVATO®, which may lead to physical and psychological dependence. Your healthcare provider should check you for signs of abuse, misuse, and dependence before and during treatment.
    • Tell your healthcare provider if you have ever abused or been dependent on alcohol, prescription medicines, or street drugs.
    • Your healthcare provider can tell you more about the differences between physical and psychological dependence in drug addiction.
  • SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS). Because of the risks for sedation, dissociation, respiratory depression, and abuse and misuse, SPRAVATO® is only available through a restricted program called the SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS) Program. SPRAVATO® can only be administered at healthcare settings certified in the SPRAVATO® REMS Program. Patients treated in outpatient healthcare settings (such as medical offices and clinics) must be enrolled in the program.
  • Increased risk of suicidal thoughts and actions. Antidepressant medicines may increase suicidal thoughts and actions in some people 24 years of age and younger, especially within the first few months of treatment or when the dose is changed. SPRAVATO® is not for use in children.
    • Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Some people may have a higher risk of having suicidal thoughts or actions. These include people who have (or have a family history of) depression or a history of suicidal thoughts or actions.
  • How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member?
    • Pay close attention to any changes, especially sudden changes, in mood, behavior, thoughts, or feelings, or if you develop suicidal thoughts or actions.
    • Tell your healthcare provider right away if you have any new or sudden changes in mood, behavior, thoughts, or feelings, or if you develop suicidal thoughts or actions.
    • Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you have concerns about symptoms.
  • Tell your healthcare provider right away if you or your family member have any of the following symptoms, especially if they are new, worse, or worry you:
    • thoughts about suicide or dying
    • new or worse depression
    • feeling very agitated or restless
    • trouble sleeping (insomnia)
    • acting aggressive, being angry or violent
    • an extreme increase in activity and talking (mania)
    • suicide attempts
    • new or worse anxiety
    • panic attacks
    • new or worse irritability
    • acting on dangerous impulses
    • other unusual changes in behavior or mood

Do not take SPRAVATO® if you:

  • have blood vessel (aneurysmal vascular) disease (including in the brain, chest, abdominal aorta, arms and legs)
  • have an abnormal connection between your veins and arteries (arteriovenous malformation)
  • have a history of bleeding in the brain
  • are allergic to esketamine, ketamine, or any of the other ingredients in SPRAVATO®.

If you are not sure if you have any of the above conditions, talk to your healthcare provider before taking SPRAVATO®.

Before you take SPRAVATO®, tell your healthcare provider about all of your medical conditions, including if you:

  • have heart or brain problems, including:
    • high blood pressure (hypertension)
    • slow or fast heartbeats that cause shortness of breath, chest pain, lightheadedness, or fainting
    • history of heart attack
    • history of stroke
    • heart valve disease or heart failure
    • history of brain injury or any condition where there is increased pressure in the brain
  • have liver problems
  • have ever had a condition called “psychosis” (see, feel, or hear things that are not there, or believe in things that are not true).
  • are pregnant or plan to become pregnant. SPRAVATO® may harm your baby. You should not take SPRAVATO® if you are pregnant.
    • Tell your healthcare provider right away if you become pregnant during treatment with SPRAVATO®.
    • If you are able to become pregnant, talk to your healthcare provider about methods to prevent pregnancy during treatment with SPRAVATO®.
    • There is a pregnancy registry for women who are exposed to SPRAVATO® during pregnancy. The purpose of the registry is to collect information about the health of women exposed to SPRAVATO® and their baby. If you become pregnant during treatment with SPRAVATO®, talk to your healthcare provider about registering with the National Pregnancy Registry for Antidepressants at 1-844-405-6185 or online at https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/antidepressants/.
  • are breastfeeding or plan to breastfeed. SPRAVATO® passes into your breast milk. You should not breastfeed during treatment with SPRAVATO®.

Tell your healthcare provider about all the medicines that you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Taking SPRAVATO® with certain medicine may cause side effects.

Especially tell your healthcare provider if you take central nervous system (CNS) depressants, psychostimulants, or monoamine oxidase inhibitors (MAOIs) medicine. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine.

How will I take SPRAVATO®?

  • You will take SPRAVATO® nasal spray yourself, under the supervision of a healthcare provider in a healthcare setting. Your healthcare provider will show you how to use the SPRAVATO® nasal spray device.
  • Your healthcare provider will tell you how much SPRAVATO® you will take and when you will take it.
  • Follow your SPRAVATO® treatment schedule exactly as your healthcare provider tells you to.
  • During and after each use of the SPRAVATO® nasal spray device, you will be checked by a healthcare provider who will decide when you are ready to leave the healthcare setting.
  • You will need to plan for a caregiver or family member to drive you home after taking SPRAVATO®.
  • If you miss a SPRAVATO® treatment, your healthcare provider may change your dose and treatment schedule.
  • Some people taking SPRAVATO® get nausea and vomiting. You should not eat for at least 2 hours before taking SPRAVATO® and not drink liquids at least 30 minutes before taking SPRAVATO®.
  • If you take a nasal corticosteroid or nasal decongestant medicine take these medicines at least 1 hour before taking SPRAVATO®.

What should I avoid while taking SPRAVATO®?

Do not drive, operate machinery, or do anything where you need to be completely alert after taking SPRAVATO®. Do not take part in these activities until the next day following a restful sleep. See “What is the most important information I should know about SPRAVATO®?”

What are the possible side effects of SPRAVATO®?

SPRAVATO® may cause serious side effects including:

See “What is the most important information I should know about SPRAVATO®?”

Increased blood pressure. SPRAVATO® can cause a temporary increase in your blood pressure that may last for about 4 hours after taking a dose. Your healthcare provider will check your blood pressure before taking SPRAVATO® and for at least 2 hours after you take SPRAVATO®. Tell your healthcare provider right away if you get chest pain, shortness of breath, sudden severe headache, change in vision, or seizures after taking SPRAVATO®.

Problems with thinking clearly. Tell your healthcare provider if you have problems thinking or remembering.

Bladder problems. Tell your healthcare provider if you develop trouble urinating, such as a frequent or urgent need to urinate, pain when urinating, or urinating frequently at night.

The most common side effects of SPRAVATO® include:

  • feeling disconnected from yourself, your thoughts, feelings and things around you
  • dizziness
  • nausea
  • feeling sleepy
  • spinning sensation
  • decreased feeling of sensitivity (numbness)
  • feeling anxious
  • lack of energy
  • increased blood pressure
  • vomiting
  • feeling drunk
  • headache
  • feeling very happy or excited

If these common side effects occur, they usually happen right after taking SPRAVATO® and go away the same day.

These are not all the possible side effects of SPRAVATO®. Call your doctor for medical advice about side effects. You may report side effects to Johnson & Johnson at 1-800-526-7736, or to the FDA at 1-800-FDA-1088.

What is SPRAVATO® (esketamine) CIII nasal spray?

SPRAVATO® is a prescription medicine used:

  • with or without an antidepressant taken by mouth, to treat adults with treatment-resistant depression (TRD)
  • with an antidepressant taken by mouth, to treat depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts or actions

SPRAVATO® is not for use as a medicine to prevent or relieve pain (anesthetic). It is not known if SPRAVATO® is safe or effective as an anesthetic medicine.

It is not known if SPRAVATO® is safe and effective for use in preventing suicide or in reducing suicidal thoughts or actions. SPRAVATO® is not for use in place of hospitalization if your healthcare provider determines that hospitalization is needed, even if improvement is experienced after the first dose of SPRAVATO®.

It is not known if SPRAVATO® is safe and effective in children.

Please see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.

SPRAVATO® is a registered trademark of Johnson & Johnson and its affiliated companies.